Cargando…
A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
Engineering dendritic cells (DCs) to treat cancer is a long sought-after goal for cell-based immunotherapies. In this review, we focus on the experience with CMN-001, formally AGS-003, a DC-based immunotherapy, employing autologous DC electroporated with autologous tumor RNA to treat subjects with m...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332239/ https://www.ncbi.nlm.nih.gov/pubmed/37387210 http://dx.doi.org/10.1080/21645515.2023.2220629 |
_version_ | 1785070402184151040 |
---|---|
author | DeBenedette, Mark Gamble, Alicia Norris, Marcus Horvatinovich, Joe Nicolette, Charles A. |
author_facet | DeBenedette, Mark Gamble, Alicia Norris, Marcus Horvatinovich, Joe Nicolette, Charles A. |
author_sort | DeBenedette, Mark |
collection | PubMed |
description | Engineering dendritic cells (DCs) to treat cancer is a long sought-after goal for cell-based immunotherapies. In this review, we focus on the experience with CMN-001, formally AGS-003, a DC-based immunotherapy, employing autologous DC electroporated with autologous tumor RNA to treat subjects with metastatic renal cell carcinoma (mRCC). We will review the early clinical development of CMN-001 up to and including deployment in a multicenter phase 3 study and provide a rationale to continue the development of CMN-001 in an ongoing randomized phase 2 study. The synergy between CMN-001 and everolimus observed in the phase 3 study provides an opportunity to design a phase 2b study building on the mechanism of action of CMN-001 and underlying immune and clinical outcomes revealed in the earlier studies. The design of the phase 2b study combines CMN-001 with first-line checkpoint inhibition therapy and second line lenvatinib/everolimus in poor-risk mRCC subjects. |
format | Online Article Text |
id | pubmed-10332239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-103322392023-07-11 A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma DeBenedette, Mark Gamble, Alicia Norris, Marcus Horvatinovich, Joe Nicolette, Charles A. Hum Vaccin Immunother Immunotherapy - Cancer Engineering dendritic cells (DCs) to treat cancer is a long sought-after goal for cell-based immunotherapies. In this review, we focus on the experience with CMN-001, formally AGS-003, a DC-based immunotherapy, employing autologous DC electroporated with autologous tumor RNA to treat subjects with metastatic renal cell carcinoma (mRCC). We will review the early clinical development of CMN-001 up to and including deployment in a multicenter phase 3 study and provide a rationale to continue the development of CMN-001 in an ongoing randomized phase 2 study. The synergy between CMN-001 and everolimus observed in the phase 3 study provides an opportunity to design a phase 2b study building on the mechanism of action of CMN-001 and underlying immune and clinical outcomes revealed in the earlier studies. The design of the phase 2b study combines CMN-001 with first-line checkpoint inhibition therapy and second line lenvatinib/everolimus in poor-risk mRCC subjects. Taylor & Francis 2023-06-30 /pmc/articles/PMC10332239/ /pubmed/37387210 http://dx.doi.org/10.1080/21645515.2023.2220629 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Immunotherapy - Cancer DeBenedette, Mark Gamble, Alicia Norris, Marcus Horvatinovich, Joe Nicolette, Charles A. A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma |
title | A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma |
title_full | A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma |
title_fullStr | A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma |
title_full_unstemmed | A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma |
title_short | A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma |
title_sort | review of the clinical experience with cmn-001, a tumor rna loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma |
topic | Immunotherapy - Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332239/ https://www.ncbi.nlm.nih.gov/pubmed/37387210 http://dx.doi.org/10.1080/21645515.2023.2220629 |
work_keys_str_mv | AT debenedettemark areviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma AT gamblealicia areviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma AT norrismarcus areviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma AT horvatinovichjoe areviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma AT nicolettecharlesa areviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma AT debenedettemark reviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma AT gamblealicia reviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma AT norrismarcus reviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma AT horvatinovichjoe reviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma AT nicolettecharlesa reviewoftheclinicalexperiencewithcmn001atumorrnaloadeddendriticcellimmunotherapyforthetreatmentofmetastaticrenalcellcarcinoma |